Drug Profile
LEO 35299
Alternative Names: LEO-35299Latest Information Update: 10 Mar 2016
Price :
$50
*
At a glance
- Originator LEO Pharma
- Class Antipsoriatics
- Mechanism of Action CXCR4 receptor antagonists; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Psoriasis
Most Recent Events
- 30 Jun 2012 LEO Pharma completes a phase I trial in Psoriasis in France (NCT01580488)
- 30 Apr 2012 Phase-I clinical trials in Psoriasis in France (Topical)
- 20 Aug 2009 Preclinical development in Psoriasis in Denmark (unspecified route)